Monopar Therapeutics (MNPR) Interest Expenses (2022 - 2023)
Quarterly results put Interest Expenses at $13.3 million for Q4 2023, up 19.07% from a year ago — trailing twelve months through Dec 2023 was $13.3 million (up 19.07% YoY), and the annual figure for FY2023 was $13.3 million, up 19.07%.
Monopar Therapeutics has reported Interest Expenses over the past 2 years, most recently at $13.3 million for Q4 2023.
- Interest Expenses reached $13.3 million in Q4 2023 per MNPR's latest filing, up from $11.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $13.3 million in Q4 2023 and bottomed at $11.1 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 12.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -332,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13.27 Mn |
| Dec 31, 2023 | 13.27 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Dec 31, 2022 | 11.14 Mn |